One of crypto’s biggest courtroom dramas is set to resume, as Sam Bankman-Fried prepares to challenge his 25-year sentence with a potential new trial on the horizon. Sam Bankman-Fried, ex-CEO of the bankrupt FTX exchange, will be making another return…One of crypto’s biggest courtroom dramas is set to resume, as Sam Bankman-Fried prepares to challenge his 25-year sentence with a potential new trial on the horizon. Sam Bankman-Fried, ex-CEO of the bankrupt FTX exchange, will be making another return…

Sam Bankman-Fried launched appeal to 25-year prison sentence

2025/09/12 17:06
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

One of crypto’s biggest courtroom dramas is set to resume, as Sam Bankman-Fried prepares to challenge his 25-year sentence with a potential new trial on the horizon.

Summary
  • SBF is gearing up to appeal his sentence.
  • Rumours allege that SBF’s arguement will be based on his trial being unfair as customer funds were not fully lost.
  • Roughly $1.9 billion in payouts is expected this September with $8 billion already returned to customers.

Sam Bankman-Fried, ex-CEO of the bankrupt FTX exchange, will be making another return to court this November, raising speculation around what his legal arguments could be.

SBF appeal date set as arguments take shape

A recent scheduling notice from the U.S. Court of Appeals for the Second Circuit confirmed that oral arguments in Sam Bankman-Fried’s appeal will be heard on Nov. 4, 2025. This is the most significant legal development since his March 2024 sentencing, where the former FTX CEO was handed 25 years in prison for seven felony counts tied to the $8 billion collapse of the crypto exchange.

The upcoming hearing will be closely watched by both the legal and crypto communities who are still skeptical about what his argument might be. His legal team initially argued that the original trial was fundamentally flawed, claiming SBF was “never presumed innocent” and that prosecutors pushed a false narrative of permanently lost customer funds.

Meanwhile, a recently pinned post on X by the disgraced mogul hints at another possible line of argument. The post details his claim that FTX’s Chapter 11 process was manipulated by external legal counsel and that valuable recovery efforts were sidelined. 

SBF alleged that Sullivan & Cromwell and John Ray III took control of FTX against his will, prioritizing legal fees over customer outcomes. If used in court, this argument may try to shift the focus from criminal intent to procedural injustice, a move that aligns with his long-standing stance that he was unfairly tried.

Although the specifics of the appeal are not known, the hearing on Nov 4 may allow a new trial or sentence hearing. Nevertheless, it will be hard to reverse such a high-profile conviction, especially with the harmful testimony of former FTX executives, such as Caroline Ellison and Gary Wang.

Rumours of pardon and pending payouts keep FTX saga alive

Beyond the appeal, SBF is also suspected of exploring other possible paths to freedom. In March, the former CEO sat down for an interview with Tucker Carlson where he hinted at a political shift toward Republican ideas, fueling speculation that he may be seeking a pardon from Donald Trump.

While SBF did not explicitly request clemency, the timing raised eyebrows, especially since Trump previously granted a pardon to Silk Road founder Ross Ulbricht, another controversial figure in the crypto space. The possibility of a pardon remains speculative but keeps Bankman-Fried in public view as legal and political narratives intersect.

On the other hand, some FTX customers are still awaiting compensation. So far, over $6.5 billion has already been returned to creditors, with an additional $1.9 billion in payouts expected this September. Nevertheless, about $1.4 billion in claims are still pending because of KYC, jurisdiction, and sanctions.

As the appeal hearing nears, the future of SBF comes into the limelight again. Whether the court grants a new trial or upholds the conviction, the outcome will resonate far beyond the courtroom, shaping future developments in the crypto space.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09